In summary, these results illustrate that trametinib can inhibit the size of the glioblastoma xenograft and expression of Ki67, ERK and PKM2 in vivo—which achieve the purpose of treating glioma through the PKM2/c-myc axis. Here, PKM is linked to glioma.